Lumens in a patient's body can change in size, shape, and/or patency, and such changes can present complications or affect associated bodily functions. For example, the walls of the vasculature, particularly arterial walls, may develop a pathological dilatation, commonly called an aneurysm. Aneurysms are observed as a ballooning-out of the wall of an artery. This is a result of the vessel wall being weakened by disease, injury, or a congenital abnormality. Aneurysms have thin, weak walls and have a tendency to rupture and are often caused or made worse by high blood pressure. Aneurysms can be found in different parts of the body; the most common being abdominal aortic aneurysms (AAA) and the brain or cerebral aneurysms. The mere presence of an aneurysm is not always life-threatening, but an aneurysm can have serious health consequences such as a stroke if one should rupture in the brain. Additionally, a ruptured aneurysm can also result in death.
The subject technology is illustrated, for example, according to various aspects described below. Various examples of aspects of the subject technology are described as numbered clauses (1, 2, 3, etc.) for convenience. These are provided as examples, and do not limit the subject technology. It is noted that any of the dependent clauses may be combined in any combination, and placed into a respective independent clause, e.g., clause 1, 18 and 27. The other clauses can be presented in a similar manner.
1. A vascular device, comprising:
2. The vascular device of clause 1, wherein the apertures are formed by displacement of adjacent strands.
3. The vascular device of clause 1, wherein the plurality of apertures comprises two apertures.
4. The vascular device of clause 2, wherein the apertures are equally spaced and radially arranged around a longitudinal axis of the body.
5. The vascular device of clause 2, wherein a center region of each of the apertures is disposed along a single radial cross section of the body.
6. The vascular device of clause 1, wherein the plurality of apertures comprises three apertures.
7. The vascular device of clause 6, wherein the apertures are equally spaced and radially arranged around a longitudinal axis of the body.
8. The vascular device of clause 6, wherein a center region of each of the apertures is disposed along a single radial cross section of the body.
9. The vascular device of clause 1, wherein the plurality of apertures comprises four apertures.
10. The vascular device of clause 9, wherein the apertures are equally spaced and radially arranged around a longitudinal axis of the body.
11. The vascular device of clause 9, wherein a center region of each of the apertures is disposed along a single radial cross section of the body.
12. The vascular device of clause 1, wherein a number of strands in each of a proximal, center, and distal radial cross sections of the body is the same.
13. The vascular device of clause 1, wherein the body has a hoop strength that is generally uniform along the body's longitudinal length.
14. The vascular device of clause 1, wherein an area of at least one of the apertures is about 0.005 square millimeters or larger.
15. The vascular device of clause 1, wherein an area of at least one of the pores is about 0.01 square millimeters or smaller.
16. The vascular device of clause 1, wherein the apertures are larger than the pores.
17. The vascular device of clause 1, wherein a thickness of each strand is about 0.0010 to 0.0014 inches.
18. A method, for creating a plurality of apertures in a vascular device, comprising:
19. The method of clause 18, wherein the plurality of apertures comprises two apertures.
20. The method of clause 18, wherein the plurality of apertures comprises three apertures.
21. The method of clause 18, wherein the plurality of apertures comprises four apertures.
22. The method of clause 18, wherein the apertures are equally spaced and radially arranged around a longitudinal axis of the vascular device.
23. The method of clause 18, wherein a center region of each of the apertures is disposed along a single radial cross section of the vascular device.
24. The method of clause 18, wherein a number of strands in each of a proximal, center, and distal radial cross sections of the vascular device is the same.
25. The method of clause 18, wherein the vascular device has a hoop strength that is generally uniform along the device's longitudinal length.
26. The method of clause 18, wherein the apertures are larger than the pores.
27. A method for providing blood flow into a perforator vessel extending from a sac of an aneurysm, the method comprising:
28. The method of clause 27, wherein the plurality of apertures comprises two apertures.
29. The method of clause 27, wherein the plurality of apertures comprises three apertures.
30. The method of clause 27, wherein the plurality of apertures comprises four apertures.
31. The method of clause 27, wherein the apertures are equally spaced and radially arranged around a longitudinal axis of the vascular device.
32. The method of clause 27, wherein a center region of each of the apertures is disposed along a single radial cross section of the vascular device.
33. The method of clause 27, wherein a number of strands in each of a proximal, center, and distal radial cross sections of the vascular device are the same.
34. The method of clause 27, wherein the vascular device has a hoop strength that is generally uniform along the device's longitudinal length.
35. The method of clause 27, wherein the apertures are larger than the pores.
It is understood that other configurations of the subject technology will become readily apparent to those skilled in the art from the following detailed description, wherein various configurations of the subject technology are shown and described by way of illustration. As will be realized, the subject technology is capable of other and different configurations and its several details are capable of modification in various other respects, all without departing from the scope of the subject technology. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not as restrictive.
A detailed description will be made with reference to the accompanying drawings:
Aneurysms may be located, for example, along vessel side walls. A neck of an aneurysm typically defines an opening of between about 2 to 25 mm, though other sizes and ranges are also possible. The neck connects an anatomical vessel lumen to a fundus of the aneurysm. In some instances, “vessel” may refer to blood vessels (including arteries and veins) or other suitable body organs having a lumen, such as the gastrointestinal tract (e.g., esophagus, stomach, small intestine, colon, rectum), bile ducts, urinary bladder, ureter, urethra, trachea, bronchi, and the like. Blood flow within the anatomical lumen is channeled through the neck and into the fundus. In response to the constant blood flow into the fundus of the aneurysm, the wall of the aneurysm continues to distend and presents a significant risk of rupturing. When the blood within the aneurysm causes pressure against the wall of the aneurysm that exceeds the wall strength, the aneurysm ruptures.
Reduction of blood flow to or within the aneurysm results in a reduction in force against the wall of the aneurysm and a corresponding reduction in the risk of rupturing. Conventionally, a reduction of the force and volume of blood entering the aneurysm may be accomplished by an occluding device. The conventional occluding device restricts blood flow to the aneurysm. The aneurysm, however, may have small perforator vessels or arteries extending from the aneurysm. Because the conventional occluding device isolates the aneurysm from the blood flow in the vessel, any small perforator arteries or vessel branches (both inlet and outlet branches) extending from the aneurysm are also occluded, thereby preventing blood from flowing into the perforator vessels.
The vascular devices of the subject technology solve some or all of the foregoing problems by sufficiently restricting the blood flow into the aneurysm to prevent rupture while providing sufficient blood flow to perforator vessels or arteries extending from the aneurysm, or extending from the parent vessel sidewall near the aneurysm neck (and/or from a location on the sidewall between the proximal and distal ends of the vascular device when deployed). The vascular device includes an expandable vascular device having one or more enlarged apertures disposed near the neck of the aneurysm. The vascular device is configured to reduce the laminar flow into the aneurysm to prevent rupture, while providing sufficient blood flow to the perforator vessel through one or more of the enlarged apertures. Accordingly, the vascular device exhibits a porosity configured to reduce haemodynamic flow into the aneurysm, but simultaneously allow perfusion to perforator vessels.
The body 110 may be a self-expanding stent made of two or more round or ovoid wire strands or filaments 112. In one aspect, the filaments may all be of the same thickness. For example, the thickness of each strand 112 may be about 0.0001 to 0.0020 inches. The filaments may be formed of known flexible and shape memory materials, such as nitinol. The filaments may be formed of platinum and stainless steel. The body 110 may be fabricated from platinum/8% tungsten and 35N LT (cobalt nickel alloy, which is a low titanium version of MP35N alloy) alloy wires. In other embodiments, one or more of the filaments can be formed of a biocompatible metal material or a biocompatible polymer, so long as the filaments are flexible and have shape memory properties. The filaments may be braided into a resulting lattice-like structure. In at least one embodiment, during braiding or winding of the body 110, the filaments may be loosely braided using a 1-over-2-under-2 system. In other embodiments, however, other methods of braiding may be followed, without departing from the scope of the disclosure.
The ends of the body 110 may be cut to length and therefore remain free for radial expansion and contraction. The body 110 may exhibit a high degree of flexibility due to the materials used, the porosity of the body 110, and the fact that the ends of the filaments are not secured to each other.
The pores 120 at the proximal and distal portions of the body 110 are sized to reduce haemodynamic flow into an aneurysm and the apertures 130 are sized to provide sufficient blood flow to any perforator vessels extending from the aneurysm. For example, an area of at least one of the pores 120 may be about 0.01 square millimeters or less and an area of at least one of the apertures 130 may be about 0.005 square millimeters or more. In some aspects, the apertures 130 are larger than the pores 120. In some embodiments, the apertures 130 are configured to be about five times the size of the pores 120. In some embodiments, the apertures 130 are sized to be range from about two to about ten times the size of the pores 120, while in some embodiments, the apertures 130 are sized to range from about three to about seven times the size of the pores 120.
The apertures 130 may be disposed at a longitudinal center region of the body 110 and be formed by displacement of adjacent strands, as shown in
In some aspects, because the pores 120 and the apertures 130 generally comprise gaps, voids, or areas that are formed between adjacent strands 112, the number of strands 112 in each of a proximal, center, and distal radial cross sections of the body 110 is the same. For example, referring to
In one aspect, the apertures 130 may be formed on the vascular device 100 by first placing the vascular device 100 in the expanded configuration on a fixture and then inserting one or more tapered mandrels, depending on the number of apertures 130, through the body 110 to displace the strands 112 and thereby form the apertures 130. The displaced strands 112 are then heated to their shape memory temperature to “set” the displaced strands in their displaced configuration. Thereafter, the one or more mandrels are removed from the body 110 and the apertures 130 remain formed on the body 110.
When the vascular device 100 is in the collapsed configuration, the displaced strands 112 forming the apertures 130 are collapsed, along with all the strands 112 comprising the body 110, and the apertures 130 and the pores 120 are substantially the same size, as shown in
In one aspect, the vascular device may be coated with an endothelial progenitor cell coating to promote endothelium growth on an inner surface of the vascular device 100. Typically, the endothelium will grow from the proximal and/or distal ends of the vascular device 100 and traverse toward the longitudinal center of the vascular device 100. The strands 112 of the vascular device 100 serve as a substrate for the cells to attach thereto. As the inner surface of the vascular device becomes endothelialized, the pores 120 are occluded. Because the apertures 130 are larger than the pores 120, the endothelium grows around the apertures 130 but does not occlude the apertures 130. Accordingly, the apertures 130 remain unobstructed and permit blood to flow therethrough to feed any perforator vessel emanating from an aneurysm fundus, or emanating from the parent vessel sidewall near the aneurysm neck (and/or from a location on the sidewall between the proximal and distal ends of the vascular device when deployed).
Radiopaque markers may be located adjacent the proximal or distal portions of the vascular device 100, and may be located at any position along the length of the vascular device 100 between a proximal and distal end of the vascular device 100. The markers may be attached to the vascular device 100 by techniques such as adhesives, heat fusion, interference fit, fasteners, intermediate members, coatings, or by other techniques.
In some embodiments, the markers are comprised of ultrasonic markers, MRI-safe markers, or other markers. In some embodiments ultrasonic markers permit a physician to accurately determine the position of the vascular device 100 within a patient under ultrasonic visualization. Materials for an ultrasonic marker have an acoustical density sufficiently different from the vascular device 100 to provide suitable visualization via ultrasonic techniques. Exemplary materials comprise polymers, metals such as tantalum, platinum, gold, tungsten and alloys of such metals, hollow glass spheres or microspheres, and other materials.
In some embodiments, MRI-safe markers permit a physician to accurately determine the position of the vascular device 100 within a patient under magnetic resonance imaging. Exemplary materials for making MRI-safe marker have a magnetic signature sufficiently different from the vascular device 100 to provide suitable visualization via MRI techniques. Exemplary materials comprise polymers, metals such as tantalum, platinum, gold, tungsten and alloys of such metals, non-ferrous materials, and other materials.
A technique for treating an aneurysm and providing blood flow into a perforator vessel extending from a sac of the aneurysm will now be discussed with reference to
Prior to delivery, an outer sheath 210 is disposed over the vascular device 100 to confine the vascular device 100 in the first, collapsed configuration. The vascular device 100 is cooperatively movable within the outer sheath 210 in order to deliver the vascular device 100 to a treatment site, such as an aneurysm 310, within the vasculature 300 of a patient.
The outer sheath 210 may be configured to be introduced and advanced through the vasculature of the patient. The outer sheath 210 may be made from various thermoplastics, e.g., PTFE, FEP, HDPE, PEEK, etc., which may optionally be lined on the inner surface of the outer sheath 140 or an adjacent surface with a hydrophilic material such as PVP or some other plastic coating. Additionally, either surface may be coated with various combinations of different materials, depending upon the desired results.
The delivery system 200 also includes a shaft 220 and a guide wire 230. The shaft 220 has a guide wire lumen for allowing the guide wire 230 to extend therethrough. The shaft 220 may also include a reduced diameter at a distal region to provide sufficient annular space in which the vascular device 100 may be stowed.
Radiopaque markers may be provided at various locations along the length of the delivery system 200. For example, an enlarged distal tip 240 of the shaft 220 may be radiopaque. In another example, radiopaque markers may be provided on the reduced diameter distal region of the shaft 220, beneath the distal and proximal end of the vascular device 100. In yet another example, a radiopaque marker 250 may be disposed on the shaft 220 adjacent to a longitudinal center of the vascular device 100, corresponding to the location of the apertures 130.
In one aspect, the vascular device 100 may be configured with differently sized apertures 130 and/or number of apertures 130. A physician may therefore select the appropriate vascular device 100 based on a size of the aneurysm and/or a number of perforators extending from the aneurysm and the diameter of each aperture 130 and/or number of apertures 130 per vascular device 100. For example, based on the diameter of each aperture 130 and the number of perforators extending from the aneurysm sac and/or from the parent vessel 300, the vascular device 100 may be selected such that the apertures 130 in fluid communication with the sac (and/or with other relevant vessel location(s)) are sufficiently large to provide sufficient blood flow to each of the perforators when the vascular device 100 is in the second, expanded configuration. The blood flow permitted by the apertures 130 to the perforators is sufficient to provide blood to downstream tissues without inducing ischemia.
In another example, based on the number of apertures 130 in the vascular device 100 and the number of perforators extending from the aneurysm sac and/or from the parent vessel 300, the vascular device 100 may be selected such that there are a sufficient number of apertures 130 in fluid communication with the sac (and/or with other relevant vessel location(s)) to provide sufficient blood flow to each of the perforators when the vascular device 100 is in the second, expanded configuration. In these applications, sufficient blood flow is provided for the perforators extending from the aneurysm sac and/or parent vessel 300 to avoid or limit ischemia to downstream tissue, but the blood flow within the aneurysm is disrupted sufficiently to permit healing of the aneurysm.
Referring to
Referring to
Referring to
In one aspect, during deployment, the position of the vascular device 100 within the vessel 300 may be further modified, if after initial partial deployment of the vascular device 100, the vascular device is positioned incorrectly or otherwise has to be relocated to properly cover the treatment site. For example, the outer sheath 210 may be advanced distally, thereby encapsulating or compressing the vascular device 100 within the outer sheath 210 and allowing the system 200 to be repositioned. Accordingly, the vascular device 100 may be partially deployed, resheathed, and relocated multiple times in order to ensure that the vascular device is properly deployed in the correct location.
In another aspect, because of the woven or braided structure of the vascular device 100, the strands of the vascular device 100 can also move relative to each other, further allowing the vascular device 100 to flex and thereby permit advancement or rotation of the unexpanded portion of the vascular device 100 against an expanded portion of the vascular device 100 that is deployed within the vessel 300. Accordingly, through rotation or positioning of the unexpanded portion relative to the expanded portion of the vascular device 100, the apertures 130 of the vascular device 100 may be properly aligned and positioned at the treatment site.
Referring to
Initially, blood may flow to the perforator vessel 320 from the plurality of pores 120 and apertures 130. As the inner surface of the vascular device 100 becomes endothelialized, the pores 120 will become occluded thereby preventing blood from flowing therethrough. The blood, however, will continue to flow through the apertures 130, thereby providing sufficient blood flow to the perforator 320.
In one arrangement, the vascular device 100 may be comprised of metal, polymer, ceramic, permanent enduring materials, and may comprise either or both of non-bioabsorbable and bioabsorbable materials. Exemplary materials include, but are not limited to, NITINOL®, stainless steel, cobalt chromium alloys, Elgiloy, magnesium alloys, polylactic acid, poly glycolic acid, poly ester amide (PEA), poly ester urethane (PEU), amino acid based bioanalogous polymers, tungsten, tantalum, platinum, polymers, bio-polymers, ceramics, bio-ceramics, or metallic glasses. Part or all of the medical device may elute over time substances such as drugs, biologics, gene therapies, antithrombotics, coagulants, anti-inflammatory drugs, immunomodulator drugs, anti-proliferatives, migration inhibitors, extracellular matrix modulators, healing promoters, re-endothelialization promoters, or other materials. In some embodiments, the vascular device 100 may be formed from materials having shape memory properties. In some embodiments, the vascular device 100 may be finished by processes to remove slag. In some embodiments, the vascular device 100 may be subjected to a tempering treatment at temperatures customarily applied to the material so that the impressed structure is permanently established.
The vascular device 100 may have various lengths and diameters. For example, the vascular device 100 may have specific cross-sectional diameters, the diameters being measured when the vascular device 110 is fully free to expand, ranging from about 2 mm to about 6 mm. If the vascular device 110 has a diameter between about 3 mm and about 4 mm, it may be used in a size 18 microcatheters (i.e., microcatheters with an inner diameter of approximately 0.21 inch). If the vascular device 100 has a diameter between about 5 mm and about 6 mm, it may be used in a size 27 microcatheters (i.e., microcatheters with an inner diameter of approximately 0.027 inch). However, other suitable cross-sectional diameters may be used without deviating from the scope of the subject technology. In some embodiments, the vascular device 100 may have lengths, measured proximally to distally along the longitudinal axis of the vascular device 100, ranging from about 15 mm to about 40 mm, though other ranges and sizes are also possible.
The detailed description set forth above is intended as a description of various configurations of the subject technology and is not intended to represent the only configurations in which the subject technology may be practiced. The appended drawings are incorporated herein and constitute a part of the detailed description. The detailed description includes specific details for the purpose of providing a thorough understanding of the subject technology. However, it will be apparent to those skilled in the art that the subject technology may be practiced without these specific details. In some instances, well-known structures and components are shown in block diagram form in order to avoid obscuring the concepts of the subject technology.
Skilled artisans may implement the described functionality in varying ways for each particular application. Various components and blocks may be arranged differently (for example, arranged in a different order, or partitioned in a different way) all without departing from the scope of the subject technology. It is understood that the specific order or hierarchy of steps in the processes disclosed is an illustration of exemplary approaches. Based upon design preferences, it is understood that the specific order or hierarchy of steps in the processes may be rearranged. Some of the steps may be performed simultaneously. The accompanying method claims present elements of the various steps in a sample order, and are not meant to be limited to the specific order or hierarchy presented.
The previous description is provided to enable any person skilled in the art to practice the various aspects described herein. The previous description provides various examples of the subject technology, and the subject technology is not limited to these examples. Various modifications to these aspects will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other aspects. Thus, the claims are not intended to be limited to the aspects shown herein, but is to be accorded the full scope consistent with the language claims, wherein reference to an element in the singular is not intended to mean “one and only one” unless specifically so stated, but rather “one or more.” Unless specifically stated otherwise, the term “some” refers to one or more. Pronouns in the masculine (for example, his) include the feminine and neuter gender (for example, her and its) and vice versa. Headings and subheadings, if any, are used for convenience only and do not limit the invention.
A phrase such as an “aspect” does not imply that such aspect is essential to the subject technology or that such aspect applies to all configurations of the subject technology. A disclosure relating to an aspect may apply to all configurations, or one or more configurations. An aspect may provide one or more examples. A phrase such as an aspect may refer to one or more aspects and vice versa. A phrase such as an “aspect” does not imply that such aspect is essential to the subject technology or that such aspect applies to all configurations of the subject technology. A disclosure relating to an aspect may apply to all aspects, or one or more aspects. An aspect may provide one or more examples. A phrase such as an “aspect” may refer to one or more aspects and vice versa. A phrase such as a “configuration” does not imply that such configuration is essential to the subject technology or that such configuration applies to all configurations of the subject technology. A disclosure relating to a configuration may apply to all configurations, or one or more configurations. A configuration may provide one or more examples. A phrase such as a “configuration” may refer to one or more configurations and vice versa.
The word “exemplary” is used herein to mean “serving as an example or illustration.” Any aspect or design described herein as “exemplary” is not necessarily to be construed as preferred or advantageous over other aspects or designs.
All structural and functional equivalents to the elements of the various aspects described throughout this disclosure that are known or later come to be known to those of ordinary skill in the art are expressly incorporated herein by reference and are intended to be encompassed by the claims. Moreover, nothing disclosed herein is intended to be dedicated to the public regardless of whether such disclosure is explicitly recited in the claims. No claim element is to be construed under the provisions of 35 U.S.C. §112, sixth paragraph, unless the element is expressly recited using the phrase “means for” or, in the case of a method claim, the element is recited using the phrase “step for.” Furthermore, to the extent that the term “include,” “have,” or the like is used in the description or the claims, such term is intended to be inclusive in a manner similar to the term “comprise” as “comprise” is interpreted when employed as a transitional word in a claim.
This application is a continuation of U.S. patent application Ser. No. 13/826,147, filed Mar. 14, 2013, now U.S. Pat. No. 9,157,174, which claims priority benefit of U.S. Provisional Application Ser. No. 61/760,907, filed Feb. 5, 2013, the entirety of each of which is hereby incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
2919467 | Mercer | Jan 1960 | A |
4321711 | Mano | Mar 1982 | A |
4503569 | Dotter | Mar 1985 | A |
4512338 | Balko et al. | Apr 1985 | A |
4538622 | Samson et al. | Sep 1985 | A |
4572186 | Gould et al. | Feb 1986 | A |
4580568 | Gianturco | Apr 1986 | A |
4655771 | Wallsten | Apr 1987 | A |
4681110 | Wiktor | Jul 1987 | A |
4733665 | Palmaz | Mar 1988 | A |
4743251 | Barra | May 1988 | A |
4768507 | Fischell et al. | Sep 1988 | A |
4776337 | Palmaz | Oct 1988 | A |
4856516 | Hillstead | Aug 1989 | A |
4954126 | Wallsten | Sep 1990 | A |
5011488 | Ginsburg | Apr 1991 | A |
5035706 | Giantureo et al. | Jul 1991 | A |
5041126 | Gianturco | Aug 1991 | A |
5061275 | Wallsten et al. | Oct 1991 | A |
5108416 | Ryan et al. | Apr 1992 | A |
5160341 | Brenneman et al. | Nov 1992 | A |
5180368 | Garrison | Jan 1993 | A |
5192297 | Hull | Mar 1993 | A |
5197978 | Hess | Mar 1993 | A |
5201757 | Heyn et al. | Apr 1993 | A |
5209731 | Sterman et al. | May 1993 | A |
5242399 | Lau et al. | Sep 1993 | A |
5246420 | Kraus et al. | Sep 1993 | A |
5246445 | Yachia et al. | Sep 1993 | A |
5330500 | Song | Jul 1994 | A |
5344426 | Lau et al. | Sep 1994 | A |
5360443 | Barone et al. | Nov 1994 | A |
5382259 | Phelps et al. | Jan 1995 | A |
5401257 | Chevalier, Jr. et al. | Mar 1995 | A |
5405377 | Cragg | Apr 1995 | A |
5405380 | Gianotti et al. | Apr 1995 | A |
5415637 | Khosravi | May 1995 | A |
5421826 | Crocker et al. | Jun 1995 | A |
5423849 | Engelson et al. | Jun 1995 | A |
5449372 | Schmaltz et al. | Sep 1995 | A |
5458615 | Klemm et al. | Oct 1995 | A |
5476505 | Limon | Dec 1995 | A |
5480423 | Ravenscroft et al. | Jan 1996 | A |
5484444 | Braunschweiler | Jan 1996 | A |
5489295 | Piplani et al. | Feb 1996 | A |
5507767 | Maeda et al. | Apr 1996 | A |
5507768 | Lau et al. | Apr 1996 | A |
5522822 | Phelps et al. | Jun 1996 | A |
5534007 | St. Germain et al. | Jul 1996 | A |
5545208 | Wolff et al. | Aug 1996 | A |
5546880 | Ronyak et al. | Aug 1996 | A |
5549662 | Fordenbacher | Aug 1996 | A |
5562641 | Flomenblit et al. | Oct 1996 | A |
5562728 | Lazarus et al. | Oct 1996 | A |
5591225 | Okuda | Jan 1997 | A |
5599291 | Balbierz et al. | Feb 1997 | A |
5601593 | Freitag | Feb 1997 | A |
5607466 | Imbert et al. | Mar 1997 | A |
5609625 | Piplani et al. | Mar 1997 | A |
5626602 | Gianotti et al. | May 1997 | A |
5628783 | Quiachon et al. | May 1997 | A |
5628788 | Pinchuk | May 1997 | A |
5632771 | Boatman et al. | May 1997 | A |
5632772 | Alcime et al. | May 1997 | A |
5636641 | Fariabi | Jun 1997 | A |
5637113 | Tartaglia et al. | Jun 1997 | A |
5639278 | Dereume et al. | Jun 1997 | A |
5645559 | Hachtman et al. | Jul 1997 | A |
D381932 | Walshe et al. | Aug 1997 | S |
5667522 | Flomenblit et al. | Sep 1997 | A |
5674276 | Andersen et al. | Oct 1997 | A |
5683451 | Lenker et al. | Nov 1997 | A |
5690120 | Jacobsen | Nov 1997 | A |
5690644 | Yurek et al. | Nov 1997 | A |
5695499 | Helgerson et al. | Dec 1997 | A |
5700269 | Pinchuk et al. | Dec 1997 | A |
5702418 | Ravenscroft | Dec 1997 | A |
5709702 | Cogita | Jan 1998 | A |
5709703 | Lukic et al. | Jan 1998 | A |
5718159 | Thompson | Feb 1998 | A |
5725570 | Heath | Mar 1998 | A |
5733327 | Igaki et al. | Mar 1998 | A |
5735859 | Fischell et al. | Apr 1998 | A |
5741325 | Chaikof et al. | Apr 1998 | A |
5741333 | Frid | Apr 1998 | A |
5746765 | Kleshinski et al. | May 1998 | A |
5749883 | Halpern | May 1998 | A |
5749920 | Quiachon et al. | May 1998 | A |
5769884 | Solovay | Jun 1998 | A |
5769885 | Quiachon et al. | Jun 1998 | A |
5776099 | Tremulis | Jul 1998 | A |
5776142 | Gunderson | Jul 1998 | A |
5782909 | Quiachon et al. | Jul 1998 | A |
5797952 | Klein | Aug 1998 | A |
5800518 | Piplani et al. | Sep 1998 | A |
5810837 | Hofmann et al. | Sep 1998 | A |
5817102 | Johnson et al. | Oct 1998 | A |
5817105 | Van Der Brug | Oct 1998 | A |
5824039 | Piplani et al. | Oct 1998 | A |
5824041 | Lenker et al. | Oct 1998 | A |
5824042 | Lombardi et al. | Oct 1998 | A |
5824044 | Quiachon et al. | Oct 1998 | A |
5824058 | Ravenscroft et al. | Oct 1998 | A |
5830229 | Konya et al. | Nov 1998 | A |
5833632 | Jacobsen et al. | Nov 1998 | A |
5836868 | Ressemann et al. | Nov 1998 | A |
5843168 | Dang | Dec 1998 | A |
5868754 | Levine et al. | Feb 1999 | A |
5876419 | Carpenter et al. | Mar 1999 | A |
5876445 | Andersen | Mar 1999 | A |
5888201 | Stinson et al. | Mar 1999 | A |
5902266 | Leone et al. | May 1999 | A |
5902317 | Kleshinski et al. | May 1999 | A |
5906640 | Penn et al. | May 1999 | A |
5911717 | Jacobsen et al. | Jun 1999 | A |
5916194 | Jacobsen et al. | Jun 1999 | A |
5919204 | Lukic et al. | Jul 1999 | A |
5928260 | Chin et al. | Jul 1999 | A |
5944728 | Bates | Aug 1999 | A |
5951599 | McCrory | Sep 1999 | A |
5957973 | Quiachon et al. | Sep 1999 | A |
5957974 | Thompson et al. | Sep 1999 | A |
5964797 | Ho | Oct 1999 | A |
5980530 | Willard | Nov 1999 | A |
5980533 | Holman | Nov 1999 | A |
5984957 | Laptewicz, Jr. et al. | Nov 1999 | A |
6012277 | Prins et al. | Jan 2000 | A |
6014919 | Jacobsen et al. | Jan 2000 | A |
6015432 | Rakos et al. | Jan 2000 | A |
6017319 | Jacobsen et al. | Jan 2000 | A |
6019778 | Wilson et al. | Feb 2000 | A |
6019786 | Thompson | Feb 2000 | A |
6022369 | Jacobsen et al. | Feb 2000 | A |
6024754 | Engelson | Feb 2000 | A |
6024763 | Lenker et al. | Feb 2000 | A |
6027516 | Kolobow et al. | Feb 2000 | A |
6033436 | Steinke et al. | Mar 2000 | A |
6039721 | Johnson | Mar 2000 | A |
6039758 | Quiachon et al. | Mar 2000 | A |
6042589 | Marianne | Mar 2000 | A |
6051021 | Frid | Apr 2000 | A |
6056993 | Leidner et al. | May 2000 | A |
6063111 | Hieshima et al. | May 2000 | A |
6074407 | Levine et al. | Jun 2000 | A |
6077295 | Limon et al. | Jun 2000 | A |
6080191 | Summers | Jun 2000 | A |
6083257 | Taylor et al. | Jul 2000 | A |
6093199 | Brown et al. | Jul 2000 | A |
6096052 | Callister et al. | Aug 2000 | A |
6102942 | Ahari | Aug 2000 | A |
6123712 | Di Caprio et al. | Sep 2000 | A |
6126685 | Lenker et al. | Oct 2000 | A |
6132459 | Piplani et al. | Oct 2000 | A |
6139543 | Esch et al. | Oct 2000 | A |
6146415 | Fitz | Nov 2000 | A |
6149680 | Shelso et al. | Nov 2000 | A |
6159228 | Frid et al. | Dec 2000 | A |
6161399 | Jayaraman | Dec 2000 | A |
6165194 | Denardo | Dec 2000 | A |
6165210 | Lau et al. | Dec 2000 | A |
6165213 | Goicoechea et al. | Dec 2000 | A |
6168592 | Kupiecki et al. | Jan 2001 | B1 |
6174330 | Stinson | Jan 2001 | B1 |
6183410 | Jacobsen et al. | Feb 2001 | B1 |
6183508 | Stinson et al. | Feb 2001 | B1 |
6187013 | Stoltze et al. | Feb 2001 | B1 |
6193708 | Ken et al. | Feb 2001 | B1 |
6197046 | Piplani et al. | Mar 2001 | B1 |
6203569 | Wijay | Mar 2001 | B1 |
6206868 | Parodi | Mar 2001 | B1 |
6210400 | Hebert et al. | Apr 2001 | B1 |
6210434 | Quiachon et al. | Apr 2001 | B1 |
6210435 | Piplani et al. | Apr 2001 | B1 |
6214038 | Piplani et al. | Apr 2001 | B1 |
6214042 | Jacobsen et al. | Apr 2001 | B1 |
6221102 | Baker et al. | Apr 2001 | B1 |
6224609 | Ressemann et al. | May 2001 | B1 |
6224829 | Piplani et al. | May 2001 | B1 |
6231598 | Berry et al. | May 2001 | B1 |
6235050 | Quiachon et al. | May 2001 | B1 |
6241759 | Piplani et al. | Jun 2001 | B1 |
6245087 | Addis | Jun 2001 | B1 |
6245103 | Stinson | Jun 2001 | B1 |
6251132 | Ravenscroft et al. | Jun 2001 | B1 |
6258115 | Dubrul | Jul 2001 | B1 |
6260458 | Jacobsen et al. | Jul 2001 | B1 |
6261305 | Marotta et al. | Jul 2001 | B1 |
6261316 | Shaolian et al. | Jul 2001 | B1 |
6264671 | Stack et al. | Jul 2001 | B1 |
6264689 | Colgan et al. | Jul 2001 | B1 |
6270523 | Herweck et al. | Aug 2001 | B1 |
6280465 | Cryer | Aug 2001 | B1 |
6283991 | Cox et al. | Sep 2001 | B1 |
6287331 | Heath | Sep 2001 | B1 |
6287333 | Appling et al. | Sep 2001 | B1 |
6290721 | Heath | Sep 2001 | B1 |
6299636 | Schmitt et al. | Oct 2001 | B1 |
6302810 | Yokota | Oct 2001 | B2 |
6302893 | Limon et al. | Oct 2001 | B1 |
6309353 | Cheng et al. | Oct 2001 | B1 |
6322576 | Wallace et al. | Nov 2001 | B1 |
6322586 | Monroe et al. | Nov 2001 | B1 |
6322587 | Quiachon et al. | Nov 2001 | B1 |
6325826 | Vardi et al. | Dec 2001 | B1 |
6334871 | Dor et al. | Jan 2002 | B1 |
6336938 | Kavteladze et al. | Jan 2002 | B1 |
6340367 | Stinson et al. | Jan 2002 | B1 |
6340368 | Verbeck | Jan 2002 | B1 |
6342068 | Thompson | Jan 2002 | B1 |
6344041 | Kupiecki et al. | Feb 2002 | B1 |
6348063 | Yassour et al. | Feb 2002 | B1 |
6350199 | Williams et al. | Feb 2002 | B1 |
6350278 | Lenker et al. | Feb 2002 | B1 |
6355051 | Sisskind et al. | Mar 2002 | B1 |
6355061 | Quiachon | Mar 2002 | B1 |
6364895 | Greenhalgh | Apr 2002 | B1 |
6368339 | Amplatz | Apr 2002 | B1 |
6368344 | Fitz | Apr 2002 | B1 |
6368557 | Piplani et al. | Apr 2002 | B1 |
6375670 | Greenhalgh | Apr 2002 | B1 |
6375676 | Cox | Apr 2002 | B1 |
6379618 | Piplani et al. | Apr 2002 | B1 |
6380457 | Yurek et al. | Apr 2002 | B1 |
6389946 | Frid | May 2002 | B1 |
6395017 | Dwyer et al. | May 2002 | B1 |
6395021 | Hart et al. | May 2002 | B1 |
6395022 | Piplani et al. | May 2002 | B1 |
6398802 | Yee | Jun 2002 | B1 |
6409683 | Fonseca et al. | Jun 2002 | B1 |
6413235 | Parodi | Jul 2002 | B1 |
6416519 | VanDusseldorp | Jul 2002 | B1 |
6416536 | Yee | Jul 2002 | B1 |
6419693 | Fariabi | Jul 2002 | B1 |
6428489 | Jacobsen et al. | Aug 2002 | B1 |
6440088 | Jacobsen et al. | Aug 2002 | B1 |
6443971 | Boylan et al. | Sep 2002 | B1 |
6443979 | Stalker | Sep 2002 | B1 |
6454999 | Farhangnia et al. | Sep 2002 | B1 |
6468301 | Amplatz et al. | Oct 2002 | B1 |
6477768 | Wildner | Nov 2002 | B1 |
6478778 | Jacobsen et al. | Nov 2002 | B1 |
6482221 | Hebert et al. | Nov 2002 | B1 |
6488705 | Schmitt et al. | Dec 2002 | B2 |
6491648 | Cornish et al. | Dec 2002 | B1 |
6494895 | Addis | Dec 2002 | B2 |
6497711 | Plaia et al. | Dec 2002 | B1 |
6503450 | Afzal | Jan 2003 | B1 |
6514261 | Randall et al. | Feb 2003 | B1 |
6514285 | Pinchasik | Feb 2003 | B1 |
6524299 | Tran et al. | Feb 2003 | B1 |
6527763 | Esch et al. | Mar 2003 | B2 |
6533811 | Ryan et al. | Mar 2003 | B1 |
6540778 | Quiachon et al. | Apr 2003 | B1 |
6547779 | Levine | Apr 2003 | B2 |
6551352 | Clerc et al. | Apr 2003 | B2 |
6572646 | Boylan et al. | Jun 2003 | B1 |
6576006 | Limon et al. | Jun 2003 | B2 |
6582460 | Cryer | Jun 2003 | B1 |
6582461 | Burmeister et al. | Jun 2003 | B1 |
6589273 | McDermott | Jul 2003 | B1 |
6592616 | Stack et al. | Jul 2003 | B1 |
6595989 | Schaer | Jul 2003 | B1 |
6602271 | Adams et al. | Aug 2003 | B2 |
6602280 | Chobotov | Aug 2003 | B2 |
6605110 | Harrison | Aug 2003 | B2 |
6613075 | Healy et al. | Sep 2003 | B1 |
6613078 | Barone | Sep 2003 | B1 |
6622604 | Chouinard et al. | Sep 2003 | B1 |
6623518 | Thompson et al. | Sep 2003 | B2 |
6635068 | Dubrul et al. | Oct 2003 | B1 |
6638243 | Kupiecki | Oct 2003 | B2 |
6645240 | Yee | Nov 2003 | B2 |
6646218 | Campbell et al. | Nov 2003 | B1 |
6652508 | Griffin | Nov 2003 | B2 |
6652574 | Jayaraman | Nov 2003 | B1 |
6656212 | Ravenscroft et al. | Dec 2003 | B2 |
6656218 | Denardo et al. | Dec 2003 | B1 |
6660024 | Flaherty | Dec 2003 | B1 |
6660032 | Klumb et al. | Dec 2003 | B2 |
6663666 | Quiachon et al. | Dec 2003 | B1 |
6666881 | Richter et al. | Dec 2003 | B1 |
6669719 | Wallace | Dec 2003 | B2 |
6673089 | Yassour et al. | Jan 2004 | B1 |
6673100 | Diaz et al. | Jan 2004 | B2 |
6679893 | Tran | Jan 2004 | B1 |
6682557 | Quiachon et al. | Jan 2004 | B1 |
6685735 | Ahari | Feb 2004 | B1 |
6689120 | Gerdts | Feb 2004 | B1 |
6689162 | Thompson | Feb 2004 | B1 |
6699274 | Stinson | Mar 2004 | B2 |
6702843 | Brown et al. | Mar 2004 | B1 |
6709454 | Cox et al. | Mar 2004 | B1 |
6712834 | Yassour et al. | Mar 2004 | B2 |
6726700 | Levine | Apr 2004 | B1 |
6733519 | Lashinski et al. | May 2004 | B2 |
6740105 | Yodfat et al. | May 2004 | B2 |
6740112 | Yodfat et al. | May 2004 | B2 |
6743219 | Dwyer et al. | Jun 2004 | B1 |
6755855 | Yurek et al. | Jun 2004 | B2 |
6758885 | Leffel et al. | Jul 2004 | B2 |
6767361 | Quiachon et al. | Jul 2004 | B2 |
6773446 | Dwyer et al. | Aug 2004 | B1 |
6793667 | Hebert et al. | Sep 2004 | B2 |
6814746 | Thompson et al. | Nov 2004 | B2 |
6814748 | Baker et al. | Nov 2004 | B1 |
6818006 | Douk et al. | Nov 2004 | B2 |
6833003 | Jones et al. | Dec 2004 | B2 |
6849084 | Rabkin et al. | Feb 2005 | B2 |
6858034 | Hijlkema et al. | Feb 2005 | B1 |
6860893 | Wallace et al. | Mar 2005 | B2 |
6860898 | Stack et al. | Mar 2005 | B2 |
6860899 | Rivelli, Jr. | Mar 2005 | B1 |
6860900 | Clerc et al. | Mar 2005 | B2 |
6860901 | Baker et al. | Mar 2005 | B1 |
6866677 | Douk et al. | Mar 2005 | B2 |
6866679 | Kusleika | Mar 2005 | B2 |
6866680 | Yassour et al. | Mar 2005 | B2 |
6881221 | Golds | Apr 2005 | B2 |
6887267 | Dworschak et al. | May 2005 | B2 |
6890337 | Feeser et al. | May 2005 | B2 |
6893451 | Cano et al. | May 2005 | B2 |
6918921 | Brady et al. | Jul 2005 | B2 |
6932837 | Amplatz et al. | Aug 2005 | B2 |
6936055 | Ken et al. | Aug 2005 | B1 |
6955685 | Escamilla et al. | Oct 2005 | B2 |
6960227 | Jones et al. | Nov 2005 | B2 |
6964670 | Shah et al. | Nov 2005 | B1 |
6964672 | Brady et al. | Nov 2005 | B2 |
6969396 | Krolik et al. | Nov 2005 | B2 |
6976991 | Hebert et al. | Dec 2005 | B2 |
6989024 | Hebert et al. | Jan 2006 | B2 |
6994721 | Israel | Feb 2006 | B2 |
7001422 | Escamilla et al. | Feb 2006 | B2 |
7004962 | Stinson | Feb 2006 | B2 |
7004964 | Thompson et al. | Feb 2006 | B2 |
7011675 | Hemerick et al. | Mar 2006 | B2 |
7037330 | Rivelli, Jr. et al. | May 2006 | B1 |
7041129 | Rourke et al. | May 2006 | B2 |
7066951 | Chobotov | Jun 2006 | B2 |
7069835 | Nishri et al. | Jul 2006 | B2 |
7074236 | Rabkin et al. | Jul 2006 | B2 |
7093527 | Rapaport et al. | Aug 2006 | B2 |
7101392 | Heath | Sep 2006 | B2 |
7107105 | Bjorklund et al. | Sep 2006 | B2 |
7118539 | Vrba et al. | Oct 2006 | B2 |
7118594 | Quiachon et al. | Oct 2006 | B2 |
7122050 | Randall et al. | Oct 2006 | B2 |
7137990 | Hebert et al. | Nov 2006 | B2 |
7166125 | Baker et al. | Jan 2007 | B1 |
7169170 | Widenhouse | Jan 2007 | B2 |
7169172 | Levine et al. | Jan 2007 | B2 |
7172617 | Colgan et al. | Feb 2007 | B2 |
7192434 | Anderson et al. | Mar 2007 | B2 |
7195639 | Quiachon et al. | Mar 2007 | B2 |
7195648 | Jones et al. | Mar 2007 | B2 |
7201768 | Diaz et al. | Apr 2007 | B2 |
7201769 | Jones et al. | Apr 2007 | B2 |
7211109 | Thompson | May 2007 | B2 |
7213495 | McCullagh et al. | May 2007 | B2 |
7220271 | Clubb et al. | May 2007 | B2 |
7235096 | Van Tassel et al. | Jun 2007 | B1 |
7264632 | Wright et al. | Sep 2007 | B2 |
7275471 | Nishri et al. | Oct 2007 | B2 |
7279005 | Stinson | Oct 2007 | B2 |
7279208 | Goffena et al. | Oct 2007 | B1 |
7294137 | Rivelli, Jr. et al. | Nov 2007 | B2 |
7294146 | Chew et al. | Nov 2007 | B2 |
7300456 | Andreas et al. | Nov 2007 | B2 |
7300460 | Levine et al. | Nov 2007 | B2 |
7306624 | Yodfat et al. | Dec 2007 | B2 |
7309351 | Escamilla et al. | Dec 2007 | B2 |
7311031 | McCullagh et al. | Dec 2007 | B2 |
7320702 | Hammersmark et al. | Jan 2008 | B2 |
7323001 | Clubb et al. | Jan 2008 | B2 |
7331973 | Gesswein et al. | Feb 2008 | B2 |
7331976 | McGuckin, Jr. et al. | Feb 2008 | B2 |
7331985 | Thompson et al. | Feb 2008 | B2 |
7338518 | Chobotov | Mar 2008 | B2 |
7438712 | Chouinard | Oct 2008 | B2 |
7462192 | Norton et al. | Dec 2008 | B2 |
7468070 | Henry et al. | Dec 2008 | B2 |
7470282 | Shelso | Dec 2008 | B2 |
7473271 | Gunderson | Jan 2009 | B2 |
7491224 | Cox et al. | Feb 2009 | B2 |
7520893 | Rivelli, Jr. | Apr 2009 | B2 |
RE40816 | Taylor et al. | Jun 2009 | E |
7572288 | Cox | Aug 2009 | B2 |
7572290 | Yodfat et al. | Aug 2009 | B2 |
7588597 | Frid | Sep 2009 | B2 |
7695507 | Rivelli, Jr. et al. | Apr 2010 | B2 |
7763011 | Ortiz et al. | Jul 2010 | B2 |
7771463 | Ton et al. | Aug 2010 | B2 |
7854760 | Molaei et al. | Dec 2010 | B2 |
7901447 | Molaei et al. | Mar 2011 | B2 |
7942925 | Yodfat et al. | May 2011 | B2 |
8007529 | Yan | Aug 2011 | B2 |
8092486 | Berrada et al. | Jan 2012 | B2 |
8092508 | Leynov et al. | Jan 2012 | B2 |
8192484 | Frid | Jun 2012 | B2 |
8382825 | Garcia et al. | Feb 2013 | B2 |
8394119 | Zaver et al. | Mar 2013 | B2 |
8398701 | Berez et al. | Mar 2013 | B2 |
8617234 | Garcia et al. | Dec 2013 | B2 |
8623067 | Berez et al. | Jan 2014 | B2 |
8628564 | Berez et al. | Jan 2014 | B2 |
8764817 | Sheldon | Jul 2014 | B2 |
8801772 | Shobayashi et al. | Aug 2014 | B2 |
8979918 | Murayama | Mar 2015 | B2 |
9050205 | Berez et al. | Jun 2015 | B2 |
9114001 | Kusleika et al. | Aug 2015 | B2 |
9125659 | Berez et al. | Sep 2015 | B2 |
20010027338 | Greenberg | Oct 2001 | A1 |
20010044651 | Steinke et al. | Nov 2001 | A1 |
20010049547 | Moore | Dec 2001 | A1 |
20010056299 | Thompson | Dec 2001 | A1 |
20020004667 | Adams et al. | Jan 2002 | A1 |
20020007194 | Plowiecki | Jan 2002 | A1 |
20020029061 | Amplatz et al. | Mar 2002 | A1 |
20020035396 | Heath | Mar 2002 | A1 |
20020062091 | Jacobsen et al. | May 2002 | A1 |
20020078808 | Jacobsen et al. | Jun 2002 | A1 |
20020082558 | Samson et al. | Jun 2002 | A1 |
20020087119 | Parodi | Jul 2002 | A1 |
20020111633 | Stoltze et al. | Aug 2002 | A1 |
20020111648 | Kusleika et al. | Aug 2002 | A1 |
20020120323 | Thompson et al. | Aug 2002 | A1 |
20020138133 | Lenz et al. | Sep 2002 | A1 |
20020143361 | Douk et al. | Oct 2002 | A1 |
20020143384 | Ozasa | Oct 2002 | A1 |
20020169473 | Sepetka et al. | Nov 2002 | A1 |
20020169474 | Kusleika et al. | Nov 2002 | A1 |
20020173839 | Leopold et al. | Nov 2002 | A1 |
20020188314 | Anderson et al. | Dec 2002 | A1 |
20020193864 | Khosravi et al. | Dec 2002 | A1 |
20030009215 | Mayer | Jan 2003 | A1 |
20030023299 | Amplatz et al. | Jan 2003 | A1 |
20030069522 | Jacobsen et al. | Apr 2003 | A1 |
20030100945 | Yodfat et al. | May 2003 | A1 |
20030130684 | Brady et al. | Jul 2003 | A1 |
20030135258 | Andreas et al. | Jul 2003 | A1 |
20030163155 | Haverkost et al. | Aug 2003 | A1 |
20030163156 | Hebert et al. | Aug 2003 | A1 |
20030176884 | Berrada et al. | Sep 2003 | A1 |
20030187495 | Cully et al. | Oct 2003 | A1 |
20030212429 | Keegan et al. | Nov 2003 | A1 |
20030212430 | Bose et al. | Nov 2003 | A1 |
20040024416 | Yodfat et al. | Feb 2004 | A1 |
20040030265 | Murayama et al. | Feb 2004 | A1 |
20040044395 | Nelson | Mar 2004 | A1 |
20040073300 | Chouinard et al. | Apr 2004 | A1 |
20040088037 | Nachreiner et al. | May 2004 | A1 |
20040093010 | Gesswein et al. | May 2004 | A1 |
20040098099 | McCullagh et al. | May 2004 | A1 |
20040133223 | Weber | Jul 2004 | A1 |
20040153117 | Clubb et al. | Aug 2004 | A1 |
20040162606 | Thompson | Aug 2004 | A1 |
20040172055 | Huter et al. | Sep 2004 | A1 |
20040186368 | Ramzipoor et al. | Sep 2004 | A1 |
20040193178 | Nikolchev | Sep 2004 | A1 |
20040193179 | Nikolchev | Sep 2004 | A1 |
20040193208 | Talpade et al. | Sep 2004 | A1 |
20040199243 | Yodfat | Oct 2004 | A1 |
20040210235 | Deshmukh et al. | Oct 2004 | A1 |
20040215332 | Frid | Oct 2004 | A1 |
20040220585 | Nikolchev | Nov 2004 | A1 |
20040220608 | D'Aquanni et al. | Nov 2004 | A1 |
20040220663 | Rivelli | Nov 2004 | A1 |
20040254628 | Nazzaro et al. | Dec 2004 | A1 |
20040260331 | D'Aquanni et al. | Dec 2004 | A1 |
20050004595 | Boyle et al. | Jan 2005 | A1 |
20050021075 | Bonnette et al. | Jan 2005 | A1 |
20050033407 | Weber et al. | Feb 2005 | A1 |
20050038447 | Huffmaster | Feb 2005 | A1 |
20050051243 | Forbes Jones et al. | Mar 2005 | A1 |
20050055047 | Greenhalgh | Mar 2005 | A1 |
20050059889 | Mayer | Mar 2005 | A1 |
20050060017 | Fischell et al. | Mar 2005 | A1 |
20050090888 | Hines et al. | Apr 2005 | A1 |
20050101989 | Cully et al. | May 2005 | A1 |
20050137680 | Ortiz et al. | Jun 2005 | A1 |
20050149111 | Kanazawa et al. | Jul 2005 | A1 |
20050165441 | McGuckin et al. | Jul 2005 | A1 |
20050177186 | Cully et al. | Aug 2005 | A1 |
20050192620 | Cully et al. | Sep 2005 | A1 |
20050197689 | Molaei | Sep 2005 | A1 |
20050209672 | George et al. | Sep 2005 | A1 |
20050209678 | Henkes et al. | Sep 2005 | A1 |
20050246010 | Alexander et al. | Nov 2005 | A1 |
20050267568 | Berez et al. | Dec 2005 | A1 |
20050283220 | Gobran et al. | Dec 2005 | A1 |
20050288764 | Snow | Dec 2005 | A1 |
20050288766 | Plain et al. | Dec 2005 | A1 |
20060020324 | Schmid et al. | Jan 2006 | A1 |
20060036309 | Hebert et al. | Feb 2006 | A1 |
20060089703 | Escamilla et al. | Apr 2006 | A1 |
20060095213 | Escamilla et al. | May 2006 | A1 |
20060111771 | Ton et al. | May 2006 | A1 |
20060116713 | Sepetka et al. | Jun 2006 | A1 |
20060116750 | Hebert et al. | Jun 2006 | A1 |
20060184238 | Kaufmann et al. | Aug 2006 | A1 |
20060195118 | Richardson | Aug 2006 | A1 |
20060206148 | Khairkhahan et al. | Sep 2006 | A1 |
20060206200 | Garcia et al. | Sep 2006 | A1 |
20060206201 | Garcia et al. | Sep 2006 | A1 |
20060212127 | Karabey et al. | Sep 2006 | A1 |
20060271149 | Berez et al. | Nov 2006 | A1 |
20060271153 | Garcia et al. | Nov 2006 | A1 |
20060276910 | Weber | Dec 2006 | A1 |
20070021816 | Rudin | Jan 2007 | A1 |
20070043419 | Nikolchev et al. | Feb 2007 | A1 |
20070055365 | Greenberg et al. | Mar 2007 | A1 |
20070060994 | Gobran et al. | Mar 2007 | A1 |
20070073379 | Chang | Mar 2007 | A1 |
20070077347 | Richter | Apr 2007 | A1 |
20070100321 | Rudakov et al. | May 2007 | A1 |
20070100414 | Licata | May 2007 | A1 |
20070100430 | Rudakov et al. | May 2007 | A1 |
20070112415 | Bartlett | May 2007 | A1 |
20070119295 | McCullagh | May 2007 | A1 |
20070123969 | Gianotti | May 2007 | A1 |
20070162104 | Frid | Jul 2007 | A1 |
20070167980 | Figulla et al. | Jul 2007 | A1 |
20070198076 | Hebert et al. | Aug 2007 | A1 |
20070203559 | Freudenthal et al. | Aug 2007 | A1 |
20070203563 | Hebert et al. | Aug 2007 | A1 |
20070208367 | Fiorella et al. | Sep 2007 | A1 |
20070208373 | Zaver et al. | Sep 2007 | A1 |
20070208376 | Meng | Sep 2007 | A1 |
20070208415 | Grotheim et al. | Sep 2007 | A1 |
20070219619 | Dieck et al. | Sep 2007 | A1 |
20070225760 | Moszner et al. | Sep 2007 | A1 |
20070233175 | Zaver et al. | Oct 2007 | A1 |
20070239261 | Bose et al. | Oct 2007 | A1 |
20070255386 | Tenne | Nov 2007 | A1 |
20070255388 | Rudakov et al. | Nov 2007 | A1 |
20070280850 | Carlson | Dec 2007 | A1 |
20070299500 | Hebert et al. | Dec 2007 | A1 |
20070299501 | Hebert et al. | Dec 2007 | A1 |
20070299502 | Hebert et al. | Dec 2007 | A1 |
20080015673 | Chuter | Jan 2008 | A1 |
20080033341 | Grad | Feb 2008 | A1 |
20080033526 | Atladottir et al. | Feb 2008 | A1 |
20080039930 | Jones et al. | Feb 2008 | A1 |
20080039933 | Yodfat | Feb 2008 | A1 |
20080071351 | Flanagan et al. | Mar 2008 | A1 |
20080082154 | Tseng et al. | Apr 2008 | A1 |
20080114391 | Dieck et al. | May 2008 | A1 |
20080119943 | Armstrong et al. | May 2008 | A1 |
20080125855 | Henkes et al. | May 2008 | A1 |
20080208320 | Tan-Malecki et al. | Aug 2008 | A1 |
20080221666 | Licata et al. | Sep 2008 | A1 |
20080221670 | Clerc et al. | Sep 2008 | A1 |
20080221671 | Chouinard et al. | Sep 2008 | A1 |
20080255654 | Hebert et al. | Oct 2008 | A1 |
20080255655 | Kusleika et al. | Oct 2008 | A1 |
20080262590 | Murray | Oct 2008 | A1 |
20080269774 | Garcia et al. | Oct 2008 | A1 |
20080275497 | Palmer et al. | Nov 2008 | A1 |
20080275498 | Palmer et al. | Nov 2008 | A1 |
20080294104 | Mawad | Nov 2008 | A1 |
20080300667 | Hebert et al. | Dec 2008 | A1 |
20080300668 | Bonsignore | Dec 2008 | A1 |
20080300673 | Clerc et al. | Dec 2008 | A1 |
20090024202 | Dave et al. | Jan 2009 | A1 |
20090024205 | Hebert et al. | Jan 2009 | A1 |
20090030496 | Kaufmann et al. | Jan 2009 | A1 |
20090030497 | Metcalf et al. | Jan 2009 | A1 |
20090054981 | Frid et al. | Feb 2009 | A1 |
20090099643 | Hyodoh et al. | Apr 2009 | A1 |
20090105802 | Henry et al. | Apr 2009 | A1 |
20090105803 | Shelso | Apr 2009 | A1 |
20090125093 | Hansen | May 2009 | A1 |
20090192536 | Berez et al. | Jul 2009 | A1 |
20090192587 | Frid | Jul 2009 | A1 |
20090198318 | Berez et al. | Aug 2009 | A1 |
20090216307 | Kaufmann et al. | Aug 2009 | A1 |
20090222035 | Schneiderman | Sep 2009 | A1 |
20090270974 | Berez et al. | Oct 2009 | A1 |
20090287241 | Berez et al. | Nov 2009 | A1 |
20090287288 | Berez et al. | Nov 2009 | A1 |
20090288000 | McPherson | Nov 2009 | A1 |
20090292348 | Berez et al. | Nov 2009 | A1 |
20090318947 | Garcia et al. | Dec 2009 | A1 |
20090319017 | Berez et al. | Dec 2009 | A1 |
20100010624 | Berez et al. | Jan 2010 | A1 |
20100042200 | Richter et al. | Feb 2010 | A1 |
20100061604 | Nahm et al. | Mar 2010 | A1 |
20100063531 | Rudakov et al. | Mar 2010 | A1 |
20100070024 | Venturelli et al. | Mar 2010 | A1 |
20100076317 | Babic et al. | Mar 2010 | A1 |
20100152834 | Hannes et al. | Jun 2010 | A1 |
20100161025 | Kuppurathanam et al. | Jun 2010 | A1 |
20100174269 | Tompkins et al. | Jul 2010 | A1 |
20100174309 | Fulkerson et al. | Jul 2010 | A1 |
20100179583 | Carpenter et al. | Jul 2010 | A1 |
20100179647 | Carpenter et al. | Jul 2010 | A1 |
20100198334 | Yodfat et al. | Aug 2010 | A1 |
20100204779 | Schuessler et al. | Aug 2010 | A1 |
20100211154 | Murayama | Aug 2010 | A1 |
20100222864 | Rivelli, Jr. et al. | Sep 2010 | A1 |
20100241214 | Holzer et al. | Sep 2010 | A1 |
20100256732 | Shin et al. | Oct 2010 | A1 |
20100256733 | Schuessler | Oct 2010 | A1 |
20100280587 | Ortiz et al. | Nov 2010 | A1 |
20100318174 | Shaolian et al. | Dec 2010 | A1 |
20100318178 | Rapaport et al. | Dec 2010 | A1 |
20110016427 | Douen | Jan 2011 | A1 |
20110040372 | Hansen et al. | Feb 2011 | A1 |
20110046718 | Cattaneo | Feb 2011 | A1 |
20110046720 | Shalev et al. | Feb 2011 | A1 |
20110054589 | Bashiri et al. | Mar 2011 | A1 |
20110166592 | Garcia et al. | Jul 2011 | A1 |
20110166637 | Irwin et al. | Jul 2011 | A1 |
20110166639 | Pulnev et al. | Jul 2011 | A1 |
20110179389 | Douen | Jul 2011 | A1 |
20110184451 | Sahl | Jul 2011 | A1 |
20110190862 | Bashiri et al. | Aug 2011 | A1 |
20110245862 | Dieck et al. | Oct 2011 | A1 |
20110270178 | Fiorella et al. | Nov 2011 | A1 |
20120035643 | Khairkhahan et al. | Feb 2012 | A1 |
20120041459 | Fiorella et al. | Feb 2012 | A1 |
20120158124 | Zaver et al. | Jun 2012 | A1 |
20120253454 | Costello | Oct 2012 | A1 |
20120290067 | Cam | Nov 2012 | A1 |
20120316638 | Grad et al. | Dec 2012 | A1 |
20120323309 | Cattaneo | Dec 2012 | A1 |
20130116773 | Roeder et al. | May 2013 | A1 |
20130123901 | Connor et al. | May 2013 | A1 |
20130138202 | Paul et al. | May 2013 | A1 |
20130172975 | Berez et al. | Jul 2013 | A1 |
20130190856 | von Oepen et al. | Jul 2013 | A1 |
20130204347 | Armstrong et al. | Aug 2013 | A1 |
20130211489 | Makower et al. | Aug 2013 | A1 |
20130211497 | Charlebois et al. | Aug 2013 | A1 |
20130274849 | Zaver et al. | Oct 2013 | A1 |
20140018843 | Berez et al. | Jan 2014 | A1 |
20140074149 | Garcia et al. | Mar 2014 | A1 |
20140121744 | Kusleika | May 2014 | A1 |
20140121746 | Kusleika et al. | May 2014 | A1 |
20140128957 | Losordo et al. | May 2014 | A1 |
20140222130 | Kusleika | Aug 2014 | A1 |
20140316454 | Zaver et al. | Oct 2014 | A1 |
20140336741 | Connor et al. | Nov 2014 | A1 |
20150305748 | Berez et al. | Oct 2015 | A1 |
20150313736 | Berez et al. | Nov 2015 | A1 |
20150359646 | Kusleika et al. | Dec 2015 | A1 |
Number | Date | Country |
---|---|---|
101472537 | Jul 2009 | CN |
855170 | Jul 1998 | EP |
1683541 | Jul 2006 | EP |
1942972 | Jul 2008 | EP |
1872742 | May 2009 | EP |
2 078 512 | Jul 2009 | EP |
2556210 | Apr 1988 | FR |
10-328216 | Dec 1998 | JP |
11-506686 | Jun 1999 | JP |
11-299901 | Nov 1999 | JP |
2001-509412 | Jul 2001 | JP |
2002-253682 | Sep 2002 | JP |
2003-520103 | Jul 2003 | JP |
2004-049585 | Feb 2004 | JP |
2005-074230 | Mar 2005 | JP |
2006-506201 | Feb 2006 | JP |
2008-502378 | Jan 2008 | JP |
2008-541832 | Nov 2008 | JP |
WO-8800813 | Feb 1988 | WO |
WO-9509586 | Apr 1995 | WO |
WO-9532757 | Dec 1995 | WO |
WO-9804211 | Feb 1998 | WO |
WO-9847447 | Oct 1998 | WO |
WO-9902092 | Jan 1999 | WO |
WO-9905977 | Feb 1999 | WO |
WO-9949812 | Dec 1999 | WO |
WO-0105331 | Jan 2001 | WO |
WO-0152771 | Jul 2001 | WO |
WO-0205729 | Jan 2002 | WO |
WO-0247579 | Jun 2002 | WO |
WO-02054988 | Jan 2003 | WO |
WO-03007840 | Jan 2003 | WO |
WO-03043527 | May 2003 | WO |
WO-03049600 | Jun 2003 | WO |
WO-03057079 | Jul 2003 | WO |
WO-03073963 | Sep 2003 | WO |
WO-2004087006 | Nov 2004 | WO |
WO-2005021061 | Mar 2005 | WO |
WO-2005023149 | Dec 2005 | WO |
WO-2006034140 | Mar 2006 | WO |
WO-2006073745 | Jul 2006 | WO |
WO-2006127005 | Nov 2006 | WO |
WO-2007122396 | Nov 2007 | WO |
WO-2008005898 | Jan 2008 | WO |
WO-2007139689 | Sep 2008 | WO |
WO-2007139699 | Sep 2008 | WO |
WO-2008156683 | Dec 2008 | WO |
WO-2005115118 | Jul 2009 | WO |
WO-2009105710 | Aug 2009 | WO |
WO-2010127838 | Nov 2010 | WO |
WO-2011023105 | Mar 2011 | WO |
WO-2011134663 | Nov 2011 | WO |
Entry |
---|
Benndorf, et al. Treatment of a Ruptured Dissecting Vertebral Artery Aneurysm with Double Stent Placement: Case Report AJNR Am J Neuroradiol, Nov.-Dec. 2001, vol. 22, pp. 1844-1848. |
Brilstra, et al., Treatment of Intracranial Aneurysms by Embolization with Coils: A Systematic Review, Stroke, Journal of the American Heart Association, 1999, vol. 30, pp. 470-476. |
Ferguson, Gary, Physical Factors in the Initiation, Growth and Rupture of Human Intracranial Saccular Aneurysms, J. Neurosurg, Dec. 1972, vol. 37, pp. 666-667. |
Geremia, et al., Embolization of Experimentally Created Aneurysms with Intravascular Stent Devices, ANJR American Journal of Neuroradiology, Aug. 1994, vol. 15, pp. 1223-1231. |
Geremia, et al., Occlusion of Experimentally Created Fusiform Aneurysms with Porous Metallic Stents, ANJR Am J Neuroradiol, Apr. 2000, Issue 21, pp. 739-745. |
Lanzino, et al., Efficacy and Current Limitations of Intravascular Stents for Intracranial Internal Carotid, Vertebral, and Basilar Artery Aneurysms, Journal of Neurosurgery, Oct. 1999, vol. 91, Issue 4, pp. 538-546. |
Lieber, et al., Alteration of Hemodynamics in Aneurysm Models by Stenting: Influence of Stent Porosity, Ann of Biomedical Eng., 1997, vol. 25, pp. 460-469, Buffalo, NY. |
Lieber, et al., The Physics of Endoluminal Stenting in the Treatment of Cerebrovascular Aneurysms, Neurological Research, 2002, Vcol 24, Issue Supplement 1, pp. S32-S42. |
Moss, et al., Vascular Occlusion with a Balloon-Expandable Stent Occluder, Radiology, May 1994, vol. 191, Issue 2, pp. 483-486. |
Pereira, Edgard, History of Endovascular Aneurysm Occlusion, Management of Cerebral Aneurysms, 2004, pp. 11-26. |
Qureshi, Adnan, Endovascular Treatment of Cerebrovascular Diseases and Intracranial Neoplasms, The Lancelet, Mar. 2004, vol. 363, pp. 804-813. |
Steiger, Pathophysiology of Development and Rupture of Cerebral Aneurysms, Acta Nurochirurgica, Mar 1990, vol. Supplementum 48, Pages in 62 pages. |
Tenaglia, et al., Ultrasound Guide Wire-Directed Stent Deployment, Duke University Medical Center, Department of Medicine, 1993 USA. |
Yu, et al., A Steady Flow Analysis on the Stented and Non-Stented Sidewall Aneurysm Models, Medical Engineering and Physics, Apr. 1999, Issue 21, pp. 133-141. |
Number | Date | Country | |
---|---|---|---|
20160022451 A1 | Jan 2016 | US |
Number | Date | Country | |
---|---|---|---|
61760907 | Feb 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13826147 | Mar 2013 | US |
Child | 14875732 | US |